Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status

Metastatic prostate cancer is a lethal disease in patients incapable of responding to therapeutic interventions. Invasive prostate cancer spread is caused by failure of the normal anti-cancer defense systems that are controlled by the tumour suppressor protein, p53. Upon mutation, p53 malfunctions....

Full description

Bibliographic Details
Main Authors: Javier Octavio Mejía-Hernández, Dinesh Raghu, Franco Caramia, Nicholas Clemons, Kenji Fujihara, Thomas Riseborough, Amina Teunisse, Aart G. Jochemsen, Lars Abrahmsén, Giovanni Blandino, Andrea Russo, Cristina Gamell, Stephen B. Fox, Catherine Mitchell, Elena A. Takano, David Byrne, Panimaya Jeffreena Miranda, Reem Saleh, Heather Thorne, Shahneen Sandhu, Scott G. Williams, Simon P. Keam, Ygal Haupt, Sue Haupt
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
MDM4
MDMX
TP53
p53
prostate cancer
eprenetapopt
Online Access:https://www.mdpi.com/2072-6694/14/16/3947

Internet

https://www.mdpi.com/2072-6694/14/16/3947

Similar Items